Key result
Novel circulating biomarkers in pathways of inflammation, thrombosis, lipoprotein metabolism, and oxidative stress are increasingly recognized for their associations with peripheral arterial disease.
Validation of novel risk factors and biomarkers for PAD may allow for earlier detection and the development of new therapies.
Peripheral arterial disease (PAD), a relatively common manifestation of atherosclerotic vascular disease, is associated with significant morbidity and mortality. Although conventional risk factors contribute to the onset and progression of PAD, the role of 'novel' biomarkers in pathways of inflammation, thrombosis, lipoprotein metabolism, and oxidative stress in determining susceptibility to PAD is being increasingly recognized. Validation of novel risk factors for PAD may allow earlier detection, an improved understanding of disease etiology and progression, and the development of new therapies. In this review, we discuss available evidence for associations between novel circulating markers and several aspects of PAD including disease susceptibility, progression, functional limitation, and adverse outcomes.
No takes yet. Share an insight, caveat, or question.
Khawaja et al. (2009) conducted a review in Peripheral arterial disease. Novel biomarkers was evaluated. Novel circulating biomarkers in pathways of inflammation, thrombosis, lipoprotein metabolism, and oxidative stress are increasingly recognized for their associations with peripheral arterial disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: